SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (3995)2/12/2016 8:20:04 PM
From: jaybe  Read Replies (1) of 4474
 
New editorial on November Blood article regarding pona resistance...

..."the efficacy of ponatinib in the patients resistant to multiple TKIs could be explained not only by its ability to inactivate BCR-ABL1 mutations, but also by its aptitude to suppress other oncogenic routes than those strictly dependent on the BCR-ABL1 TK activity. Indeed ponatinib is known to be a multikinase inhibitor. This consideration may support a more extensive investigation of the efficacy of ponatinib, either in early chronic-phase CML, because of its ability to suppress mutations and controvert genomic instability, as well as in Ph-negative hematologic malignancies, owing to its multitarget activity."

bloodjournal.org


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News